Communiqués Eckert & Ziegler SE London S.E.

Actions

0NZY

DE0005659700

Equipement et technologie médicale avancés

Marché Fermé - London S.E. Autres places de cotation 17:30:00 03/08/2026			Après clôture 21:59:13
13,65 ^EUR	-1,30%		13,56	-0,70%

22/07	Eckert & Ziegler : la Bafin examine le bilan 2024 suite à la scission de Pentixapharm	DP
22/07	Eckert & Ziegler dans le viseur de la Bafin : le cours se redresse	DP

Communiqués

22/07	BaFin Review Concerns Recognition of Pentixapharm Spin-off in 2024 Consolidated Financial Statements. Potential Income from Discontinued Operations Without Impact on Operating Key Figures.	EQ
24/06	Eckert & Ziegler : Annual General Meeting Approves Significantly Higher...	PU
24/06	Eckert & Ziegler SE Annual General Meeting Approves Significantly Higher Dividend	EQ
11/06	Eckert & Ziegler and DC Pharma Open Commercial Medical Isotope Production Site in Jintan	EQ
29/05	Eckert & Ziegler Organizes Fourth Boston Radionuclide Theranostics Forum	EQ
28/05	Eckert & Ziegler Enters Partnership with Thor Medical to Enable Access of Lead-212 for the Pharmaceutical Industry	EQ
22/05	Eckert & Ziegler Receives “Best Managed Companies Award” Once Again	EQ
13/05	Eckert & Ziegler : Invitation and Agenda AGM Eckert & Ziegler 2026 (Invitation and Agenda AGM Eckert Ziegler 2026)	PU
13/05	Eckert & Ziegler : Proposal on the appropriation of net income Eckert & Ziegler for the FY 2025 (Proposal on the appropriation of net income 2025)	PU
13/05	Eckert & Ziegler : Report of the Supervisory Board FY 2025 (Report of the Supervisory Board)	PU
13/05	Eckert & Ziegler : Report of the Management Board to the Annual General Meeting pursuant to Sections 203(2), second sentence, and 186(4), second sentence, of the German Stock Corporation Act (AktG) (Report of the Executive Board to the Annual General Meeting Item 9 2025 )	PU
13/05	Eckert & Ziegler : Remuneration System Executive Board 2025 (Remuneration System Executive Board)	PU
12/05	Eckert & Ziegler : Presentation Q1/2026 (12/05/2026)	PU
12/05	Eckert & Ziegler with a Successful Start to the Year. 2026 Forecast Confirmed.	EQ
12/05	Eckert & Ziegler : Quarterly Report I / 2026	PU
14/04	Eckert & Ziegler: Metzler Initiates Coverage with a Buy Rating and a Price Target of € 21.00. Upside Potential: 41%	EQ
10/04	Eckert & Ziegler Secures Patient Access to Critical Eye Cancer Treatment with MDR Certification for Ru-106 Eye Applicators	EQ
26/03	Eckert & Ziegler : Presentation FY 2025 (26/03/2026)	PU
26/03	Eckert & Ziegler: Strong FY 2025 with Positive Outlook	EQ
24/03	Eckert & Ziegler SE: Dr. Gunnar Mann, Allocation of 12,545 shares as part of executive board remuneration (own shares of the issuer). This is a share-based remuneration with an automatic ...	EQ
24/03	Eckert & Ziegler SE: Dr. Harald Hasselmann, Allocation of 62,541 shares as part of executive board remuneration (own shares of the issuer). This is a share-based remuneration with an ...	EQ
06/03	Eckert & Ziegler Plans Dividend of € 0.22 per Share for 2025	EQ
26/02	Eckert & Ziegler Enters Partnership with Molecular Partners to Support Development of Radio-DARPin Therapeutics	EQ
24/02	Eckert & Ziegler SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements	EQ
16/02	Eckert & Ziegler and UJF Significantly Increase Production Volume for Actinium-225	EQ